Correction Volume 13, Issue 9 pp 13372—13373
Correction for: miR-150-5p suppresses tumor progression by targeting VEGFA in colorectal cancer
- 1 General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu, China
- 2 Medical College, Southeast University, Nanjing 210009, Jiangsu, China
Received: April 7, 2021 Accepted: April 30, 2021 Published: May 14, 2021https://doi.org/10.18632/aging.203069
How to Cite
Copyright: © 2021 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article has been corrected: The authors replaced panel D of Figure 7, where the images of HCT116/siVEGFA-1 and HCT116/siVEGFA-2 were identical, because the image HCT116/siVEGFA-1 was accidentally used twice. The correct image of HCT116/siVEGFA-2 from the original set of experiments was used for new panel 7D, which is provided below.
The authors replaced panel B of Supplementary Figure 1, where the images of HCT8/agomiR-NC (0 h) group and agomiR-150-5p+vector (24h) group were used instead of the images of HCT8/agomiR-150-5p group (0, 24h). The correct images of HCT8/agomiR-150-5p group (0, 24h) from the original set of experiments were used for new panel S1B. Additionally, authors added 0 and 24h marks to the panel S1B, which is provided below.
Authors deeply apologize for these errors and testify that these alterations do not affect the results or conclusions of this work.
Figure 7. VEGFA knockdown significantly inhibited CRC progression. (A) VEGFA expression was downregulated in HCT116 and HCT8 cells transfected with siVEGFA-1 or siVEGFA-2. (B-E) VEGFA knockdown inhibited CRC cell proliferation (B), migration (C), invasion (D) and HUVECs tube formation (E). Data are shown as the meanv±SD of three independent experiments. *p<0.05, **p<0.01, ***p<0.001.